Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Share-based Compensation: 2016-2025

Historic Share-based Compensation for Collegium Pharmaceutical (COLL) over the last 10 years, with Sep 2025 value amounting to $9.8 million.

  • Collegium Pharmaceutical's Share-based Compensation rose 34.09% to $9.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.7 million, marking a year-over-year increase of 24.97%. This contributed to the annual value of $32.4 million for FY2024, which is 19.40% up from last year.
  • According to the latest figures from Q3 2025, Collegium Pharmaceutical's Share-based Compensation is $9.8 million, which was down 9.31% from $10.8 million recorded in Q2 2025.
  • Over the past 5 years, Collegium Pharmaceutical's Share-based Compensation peaked at $11.5 million during Q1 2025, and registered a low of $4.9 million during Q4 2021.
  • Moreover, its 3-year median value for Share-based Compensation was $7.5 million (2024), whereas its average is $8.3 million.
  • As far as peak fluctuations go, Collegium Pharmaceutical's Share-based Compensation dropped by 20.90% in 2021, and later spiked by 54.17% in 2025.
  • Collegium Pharmaceutical's Share-based Compensation (Quarterly) stood at $4.9 million in 2021, then grew by 15.43% to $5.7 million in 2022, then grew by 23.49% to $7.0 million in 2023, then grew by 8.48% to $7.6 million in 2024, then soared by 34.09% to $9.8 million in 2025.
  • Its Share-based Compensation was $9.8 million in Q3 2025, compared to $10.8 million in Q2 2025 and $11.5 million in Q1 2025.